

PAKISTAN FERTILIZER SECTOR

Pricing power remains intact amidst low inventory levels

Tuesday, July 27, 2021

As per the latest numbers released by NFDC, urea offtake declined by 41% YoY to 0.69Mn tons in Jun'21 due to high-base effect (1.2Mn tons in SPLY). To recall, sales crossed the 1.0Mn mark in Jun'20 amid clarification on the subsidy front and pre-buying by dealers in anticipation of hike in gas prices. DAP offtake also dropped by 61% YoY to 68K tons in Jun'21 owing to lower inventory levels driven by supply disruptions in the global market. On the other hand, we reiterate that the pricing power of fertilizer players is still strong (lower urea inventory levels of 0.43Mn tons in Jun'21), which is evident from the recent increase in urea prices by PKR 50/bag (effective from Aug'21). DAP prices are also on an uptrend with a recent price hike of PKR 200/bag in Jul'21. That said, our top picks in the sector are FFC and FFBL with Jun'22 TP of PKR 135 and PKR 35 (potential upside of 25% and 29%), respectively.

High-base effect pulls down urea sales: Urea production increased by 9% YoY to 0.51Mn tons in Jun'21, while it dropped by 14% MoM mainly due to curtailed gas supply resulting from the turnaround of KPD gas field and RLNG crisis in the country. On the other hand, the high-base effect dragged down urea sales by 41% YoY to 0.69Mn tons in Jun'21. Recall that urea offtake was higher in SPLY amid pre-buying by dealers in anticipation of hike in gas prices and clarification on the subsidy front. Sequentially, sales were up by 38% due to seasonal factors. Company-wise, FFBL, EFERT, and FFC witnessed a drop in sales in Jun'21 by 65%, 50%, and 45% YoY to 54K, 256K, and 247K tons, respectively. However, FATIMA's offtake surged by 2.4x to 105K ton owing to the production by LNG-based plants.


DAP sales drop to 68K tons: DAP offtake declined by 61% YoY (and MoM) to 68K tons in Jun'21 on account of lower inventory levels due to supply disruptions in the global market. Int'l DAP prices have been up by around 56% since CYTD (currently above USD 600/ton) owing to global commodity shortage and an uptick in energy prices. Since nearly 60% of DAP is imported in the country, local prices have also surged to new highs, hovering between PKR 5,700-5,800/bag to pass on the rising import costs (recently increased by PKR 200/bag in Jul'21). FFBL, being the only local producer of DAP, is expected to continue to capitalize on the strong pricing dynamics. Note that phosphoric acid prices have also recently risen to USD 1,160/ton (↑ 68% YoY), shrinking local DAP margins from USD 250/ton to USD 174/ton currently. However, we believe that the company is in a favourable position to pass on the impact of higher

Table 1: Fertilizer statistics for Jun'21

Ktons	June-21	June-20	YoY (%)	May-21	% MoM	1HCY21	1HCY20	YoY (%)
Urea Off-take								
FFC	247	453	-45%	183	35%	1131	1271	-11%
EFERT	256	511	-50%	200	28%	1168	869	34%
FATIMA	105	43	141%	48	119%	324	245	32%
FFBL	54	153	-65%	58	-8%	219	265	-17%
Total	690	1,160	-41%	501	38%	2,899	2,666	9%
DAP Off-take								
FFC	1	11	-92%	30	-97%	65	42	55%
EFERT	12	34	-65%	27	-55%	96	109	-12%
FFBL	23	55	-58%	69	-66%	230	251	-8%
Total	68	176	-61%	173	-61%	601	598	1%

Source: NFDC, BMA Research

Fertilizer Performance vs. KSE-100 Index



Noor Huda Shaikh

Research Analyst

Tel: 111-262-111 ext. 2053

E-mail: noor.shaikh@bmacapital.com

BMA Capital Management Ltd.

input costs as the supply-demand in the international DAP market is likely to continue in the near-term. As per our estimates, every USD 10/ton change in primary margins has an earnings impact of PKR 0.68/sh for FFBL.

Urea inventory clocked-in at 0.43Mn tons: Due to closure of RLNG-based plants during the end of Jun'21, urea inventory moderated to 0.43M tons, down 30% MoM. Our expectation for year-end inventory is between 0.35-0.40Mn tons. We reiterate that the pricing power of fertilizer players is still intact given the low levels of inventory (as suggested by historical trend; see chart 3) and widening disparity between local and international urea prices (domestic prices are trading at a discount of over 60%). As expected, EFERT and FFC have recently raised urea prices by PKR 50/bag (effective from Aug'21), taking current Dealer Transfer Prices to around PKR 1,720/bag. Other players are likely to follow suit soon. We expect this increase to have an earnings impact of PKR 1.3, PKR 1.1, PKR 0.3, and PKR 0.2 per share for FFC, EFERT, FFBL, and FATIMA, respectively.

Table 2: Urea inventory levels


Ktons	June-21	June-20	YoY (%)	May-21	% MoM	1HCY21	1HCY21	YoY (%)
FFC	93	16	497%	168	-45%	93	16	497%
EFERT	118	269	-56%	190	-38%	118	269	-56%
FATIMA	147	111	33%	166	-11%	147	111	33%
FFBL	11	1	N/A	27	-58%	11	1	N/A
Total	432	414	4%	612	-30%	432	414	4%

Source: NFDC, BMA Research


Investment Outlook: Given the strong pricing dynamics and improving farm economics, we have an overweight stance on the fertilizer sector, with FFC and FFBL as our top picks at Jun'22 TP of PKR 135 and PKR 35, respectively. Key **downside risks** include: 1) gas curtailment, 2) weak farm economics, and 3) higher than expected increase in gas prices and other input costs.

Chart 1: Urea offtake is up by 9% YoY in 1 HCY21 at 2.9Mn tons

Chart 2: DAP prices reach record highs




Source: NFDC, BMA Research



Source: NFDC, Bloomberg, BMA Research

Chart 3: Historical trend suggests that lower inventory levels increase the pricing power of fertz players



Source: NFDC, PBS, BMA Research

Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Buy	>15% expected total return
Hold	10%-15% expected total return
Underperform	<10% expected total return
*Total stock return = capital gain + dividend yield	

Old rating system

Overweight	Total sector return > expected market return
Marketweight	Expected market return
Underweight	Total stock return < expected market return

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)